Gangtok Chronicle

Parenteral Nutrition Market Size Will Grow to USD 9,158.7 Million by 2026 | B. Braun Melsungen AG, Fresenius Kabi AG, Hospira, etc

 Breaking News
  • No posts were found

Parenteral Nutrition Market Size Will Grow to USD 9,158.7 Million by 2026 | B. Braun Melsungen AG, Fresenius Kabi AG, Hospira, etc

May 04
14:05 2021
Parenteral Nutrition Market Size Will Grow to USD 9,158.7 Million by 2026 | B. Braun Melsungen AG, Fresenius Kabi AG, Hospira, etc

Parenteral Nutrition Market
Parenteral Nutrition Market Size – USD 6,018.4 Million in 2020, Market Growth – CAGR of 5.3%, Market Trends – Product launches and increased awareness of Parenteral Nutrition

The Global Parenteral Nutrition Market was valued at USD 6,018.4 Million in 2020 and is expected to reach USD 9,158.7 Million by 2028, at a CAGR of 5.3%. Parenteral nutrition, or intravenous nutrition, is a method of bringing nutrition to your body through the veins. This form of diet is used to help people who cannot draw their essential nutrients from food. It has become a well-established intervention for the following indications: to maintain the lives of patients with short bowel syndrome; for perioperative use in patients with nutritional deprivation; to improve the quality of life of patients with inflammatory bowel disease; to help with the healing of enter-cutaneous and pancreatic fistulas. Also, used widely for hypermetabolic conditions such as sepsis, trauma, burns, and acquired immune deficiency syndrome; in neonatal and pediatric patients. It is considered to be a crucial source for meeting the nutritional needs of the body, especially in cancer patients. According to the World Health Organization, cancer is the second leading cause of death in the world and is responsible for about 9.6 million deaths in 2018. Worldwide, approximately one in six deaths are due to cancer. With an increase in the number of cancer cases, the demand is expected to increase with a high CAGR. In addition to cancer, other health issues such as Crohn’s disease, ischemic bowel disease, and increased prevalence of chronic diseases have increased adoption provide patients with essential nutrients. These nutrients are vital for maintaining high levels of energy, hydration, and strength. Besides, the growing gap between needs and the actual absorption of essential nutrients into the body is fueling up the industry.

Increase in geriatric population has led to an increase in the number of patients being admitted in the healthcare institutions and hospital eventually increasing the demand. Growing awareness and rise in disposable income has led to an increased adoption. Rising metabolic disorders and chronic illness is expected to further drive the growth of the industry. However, strict rules and regulations laid down by the government associated with approval of parenteral nutrition and lack of awareness among the people are the major hindrance for industry during 2021-2028.

Get a sample of the report @

 Further key findings from the report suggest

  • Parenteral Nutrition market is growing at a CAGR of 4% in Asia Pacific followed by North America and Europe, with 5.8 % and 5.5% CAGR, respectively. High prevalence of chronic diseases among the geriatric population is expected to drive the market growth.
  • As of 2018, Single Dose Amino Acid Solution is the dominating the industry which holds 32.7% of the global market. North American regional market is the chief revenue generating source for this product segment, followed by Europe and Asia-Pacific regions
  • It is also considered to be a life-saving therapy, but it is complex. Some of these complications include infection, metabolic; however, management by an interdisciplinary nutritional support team can optimize outcomes for patients associated with this therapy.
  • Diseases of the bloodlines through which nutrition is administered can be severe and require interruption of diet, antibiotic intake, and line exchange which are some of the complications encountered during therapy.
  • Increased collaboration and partnership among key players is expected to increase the market share in the upcoming years. For example, Baxter International Inc. and Laboratoire Aguettant SAS have signed an exclusive worldwide licensing and distribution agreement for micronutrients, which are essential micronutrients used in therapy.
  • Increased government and non-governmental organization initiatives can increase the industry share. For example, on October 10, 2018, the American Parenteral and Enteral Nutrition Society (ASPEN), an organization that promotes the science and practice of clinical nutrition, and Baxter International Inc., a world leader in nutrition Clinical has published a series of educational videos on the proper use of parenteral nutrition.
  • To increase the market share, manufacturers are introducing new client-centered therapies. For example, infusion therapy, depending on the underlying disease, the solution contains a suitable active pharmaceutical ingredient.
  • In addition, the launch of innovative and compelling products is driving the growth of the market due to increased adoption. For example, the Celsite Power, injectable access ports, launched by B. Braun Melsungen offer high security and reliability to patients, nurses, doctors, and hospital administrators.
  • Key participants include Baxter International Inc.; Grifols International S.A.; Actavis Inc.; B. Braun Melsungen AG; Fresenius Kabi AG; Hospira Inc., Claris Lifesciences Limited, Sichuan Kelun Pharmaceutical, Pfizer and Aculife (Nirlife).

For the purpose of this report, Reports and Data has segmented the Parenteral Nutrition market on the basis of nutrient type, consumer type, end use, and region:

Nutrient Type (Revenue, USD Million; 2018–2028)

  • Carbohydrates
  • Lipid Emulsion
  • Single Dose Amino Acid Solution
  • Trace Elements
  • Vitamins & Minerals

Consumer Type (Revenue, USD Million; 2018–2028)

  • Children & New-born
  • Adults

End Use (Revenue, USD Million; 2018–2028)

  • Hospital
  • Clinic
  • Others

Regional Outlook (Revenue in USD Million; 2018–2028)

  • North America
    • S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America
    • Brazil

Request customization of the report @

Table of Contents

Chapter 1. Market Synopsis
    1.1. Market Definition
    1.2. Research Scope & Premise
    1.3. Methodology
    1.4. Market Estimation Technique

Chapter 2. Executive Summary
    2.1. Summary Snapshot, 2020 – 2028

Chapter 3. Indicative Metrics
    3.1. Wide range of applicability of the parenteral nutrition
    3.2. Increasing scarcity in the nutritious diet
    3.3. Growing geriatric population
    3.4. Government rules and regulations

Chapter 4. Parenteral Nutrition Segmentation & Impact Analysis
    4.1. Parenteral Nutrition Segmentation Analysis
    4.2. Parenteral Nutrition Market Value Chain Analysis, 2018 – 2028
    4.3. Regulatory framework
    4.4. Parenteral Nutrition Market Impact Analysis
         4.4.1. Market driver analysis
        High prevalence of chronic diseases
        Increased adoption by the patients
         4.4.2. Market restraint analysis
        Lack of awareness
        Increased associated side-effects
    4.5. Key opportunities prioritized
    4.6. Parenteral Nutrition Pricing Analysis
    4.7. Industry analysis – Porter’s
    4.8. Parenteral Nutrition PESTEL Analysis

Chapter 5. Parenteral Nutrition Market By Nutrient Type Insights & Trends

Chapter 6. Parenteral Nutrition Market By Consumer Type Insights & Trends

Chapter 7. Parenteral Nutrition Market By End Use Insights & Trends

Chapter 8. Parenteral Nutrition Market Regional Outlook

Chapter 9. Competitive Landscape

Chapter 10. Company Profiles
    10.1. Baxter International Inc.
            10.1.1. Company Overview
            10.1.2. Financial Performance
            10.1.3. Product Length Benchmarking
            10.1.4. Strategic Initiatives
    10.2. Grifols International S.A.
            10.2.1. Company Overview
            10.2.2. Financial Performance
            10.2.3. Product Length Benchmarking
            10.2.4. Strategic Initiatives
    10.3. Actavis Inc. Bristol-Myers Squibb
            10.3.1. Company Overview
            10.3.2. Financial Performance
            10.3.3. Product Length Benchmarking
            10.3.4. Strategic Initiatives
    10.4. B. Braun Melsungen AG
            10.4.1. Company Overview
            10.4.2. Financial Performance
            10.4.3. Product Length Benchmarking
            10.4.4. Strategic Initiatives
    10.5. Fresenius Kabi AG
            10.5.1. Company Overview
            10.5.2. Financial Performance
            10.5.3. Product Length Benchmarking
            10.5.4. Strategic Initiatives
    10.6. Hospira Inc.
           10.6.1. Company Overview
           10.6.2. Financial Performance
           10.6.3. Product Length Benchmarking
           10.6.4. Strategic Initiatives
    10.7. Claris Lifesciences Limited
            10.7.1. Company Overview
            10.7.2. Financial Performance
            10.7.3. Product Length Benchmarking
            10.7.4. Strategic Initiatives
    10.8. Sichuan Kelun Pharmaceutical Co.
            10.8.1. Company Overview
            10.8.2. Financial Performance
            10.8.3. Product Length Benchmarking
            10.8.4. Strategic Initiatives
    10.9. Pfizer
           10.9.1. Company Overview
           10.9.2. Financial Performance
           10.9.3. Product Length Benchmarking
           10.9.4. Strategic Initiatives
    10.10. Aculife (Nirlife)
             10.10.1. Company Overview
             10.10.2. Financial Performance
             10.10.3. Product Length Benchmarking
             10.10.4. Strategic Initiatives


Thank you for reading our report. For further information or query regarding the report or its customization, please connect with us. Our team will ensure you get a report well-suited to your needs.

Media Contact
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Phone: +1-212-710-1370
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States

Warning: count(): Parameter must be an array or an object that implements Countable in /home/ghaziabadonline/ on line 5